Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Technology appraisal guidance
Reference number: TA212
Published: 15 December 2010

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive
13 May 2013
(274.68 Kb 20 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 10 May 2013